BioControl Implants Congestive Heart Failure Device
August 1, 2007 - BioControl Medical announced that cardiologists at University Hospital Mannheim in Germany and at Ospedali Riuniti di Bergamo in Italy have successfully implanted the CardioFit device in the first patients to be enrolled at those sites in BioControl’s international, multi-center clinical study of the CardioFit system, marking an important step for the treatment of advanced congestive heart failure.
The CardioFit system works by applying electrical impulses to the vagus nerve. A sensing electrode in the right ventricle detects the patient’s heart rate and is used to control nerve stimulation.
The Bergamo and Mannheim hospitals join four other sites in Europe actively enrolling patients for the CardioFit system study that will include a total of 30 patients worldwide.
For more information: www.biocontrol-medical.com
More like this
- Biocontrol Medical Launches the INOVATE-HF IDE Study of its Cardiofit System for Heart Failure
- FDA Approves Full Expansion of BioControl Medical’s INOVATE-HF Study of the CardioFit
- BioControl Medical Gets Nod to Begin Second Phase of the INOVATE-HF Study of Its CardioFit System
- BioControl Medical
- European Journal of Heart Failure Lauds Biocontrol Medical’s Research on Vagus Nerve Stimulation for Treating HF